SCHEMBL3153389

SCHEMBL3153389

COc1ccccc1CC1(NC(=O)c2ccc(S(=O)(=O)Nc3nccs3)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
MAPK1 P28482 2/20 0.54
LMNA P02545 1/20 0.54
GAA P10253 1/20 0.54
ALOX12 P18054 1/20 0.54
SCN3A Q9NY46 3/20 0.53
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
POLB P06746 1/20 0.51
PKM P14618 3/20 0.49
PTPN1 P18031 1/20 0.49
PTPN11 Q06124 1/20 0.49
PTPN22 Q9Y2R2 1/20 0.49
SCN9A Q15858 5/20 0.48
CCNT1 O60563 1/20 0.47
CDK9 P50750 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3258222 0.86 SCN3A (0.56) ALDH1A1LMNAALOX12SCN3AMEN1
SCHEMBL3168911 0.84 PTPN1 (0.63) ALDH1A1ALOX12SCN3AMEN1KMT2A
SCHEMBL3158971 0.83 SCN3A (0.70) ALDH1A1MAPK1LMNAGAAALOX12
SCHEMBL3158690 0.83 SCN3A (0.54) ALDH1A1MAPK1LMNAGAAALOX12
SCHEMBL3169833 0.82 SCN3A (0.62) ALDH1A1MAPK1LMNAGAAALOX12
SCHEMBL14777740 0.80 SCN3A (0.56) ALDH1A1MAPK1SCN3AMEN1KMT2A
SCHEMBL3259307 0.79 LMNA (0.60) ALDH1A1LMNAALOX12SCN3AMEN1
SCHEMBL3258616 0.78 SCN3A (0.56) LMNAALOX12SCN3AMEN1KMT2A
SCHEMBL3161154 0.75 SCN3A (0.62) ALDH1A1LMNASCN3AMEN1KMT2A
SCHEMBL16646015 0.75 ALOX12 (0.81) ALDH1A1MAPK1LMNAGAAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 ALDH1A1 3113/4885MAPK1 1454/4885LMNA 3442/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 ALDH1A1 3113/4885MAPK1 1454/4885LMNA 3442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.